Royal Bank of Canada reiterated their outperform rating on shares of Pyxis Oncology (NASDAQ:PYXS – Free Report) in a research note released on Friday morning, Benzinga reports. The firm currently has a $7.00 price objective on the stock. PYXS has been the topic of several other reports. Leerink Partnrs reissued an outperform rating on shares […]
Related Keywords
Blackrock , Nova Scotia , Canada , Leerink Partnrs , Blackrock Inc , Vanguard Group Inc , Royal Bank , Pyxis Oncology Inc , Citadel Advisors , Pyxis Oncology , Free Report , Get Free Report , Pyxis Oncology Daily , Nasdaq Pyxs , Pyxs , Medical , Reiterated Rating , Royal Bank Of Canada ,
comparemela.com © 2020. All Rights Reserved.